Online inquiry

IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3824MR)

This product GTTS-WQ3824MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets NCAM1 gene. The antibody can be applied in Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000615.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4684
UniProt ID P13591
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3824MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12076MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MOR-00208
GTTS-WQ7337MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ1433MR IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ACC-001
GTTS-WQ15395MR IVTScrip™ mRNA-Anti-HAVCR2, TSR-022(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA TSR-022
GTTS-WQ13523MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRX-003
GTTS-WQ5227MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ4083MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BI 836
GTTS-WQ13487MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRTX-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW